MedTrace Logo

Individualized Dose Prescription in Advanced Stage Lung Cancer Patients Using Modern (Chemo)Radiotherapy

NCT01577212 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2015-11-09

No results posted yet for this study

Summary

The aim of this present study is to test the feasibility and toxicity of individualized hypofractionated radiotherapy, and to report outcome data. In case this phase II trial has favorable results, a phase II/III trial on maximally tolerable, individualized, hypofractionated radiotherapy within a shorter overall-treatment time is aimed for.

Conditions

  • Stage III Non-small Cell Lung Cancer
  • Individualized Radiation Dose Escalation

Interventions

RADIATION

Individualized dose escalation

Individualized dose escalation on the basis of the maximally tolerable dose to organs at risk - lung, esophagus, spinal cord, heart, brachial plexus

Sponsors & Collaborators

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • Jan Bussink, MD PhD · Radboud University Medical Center

  • Esther GC Troost, MD PhD · Radboud University Medical Center

  • Robin Wijsman, MD · Radboud University Medical Center

  • Aswin L Hoffmann, MSc · Maastro Clinic, The Netherlands

  • Lioe-Fee de Geus-Oei, MD PhD · Radboud University Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2014-09-30
Completion
2014-09-30

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01577212 on ClinicalTrials.gov